Label: PAROMOMYCIN SULFATE - paromomycin sulfate capsule
- NDC Code(s): 23155-038-01
- Packager: Heritage Pharmaceuticals Inc.
- Category: HUMAN PRESCRIPTION DRUG LABEL
- DEA Schedule: None
- Marketing Status: Abbreviated New Drug Application
If you are a consumer or patient please visit this version.
Paromomycin sulfate is a broad spectrum antibiotic produced by Streptomyces riomosus var. paromomycinus. It is a white, amorphous, stable, water-soluble product. Paromomycin sulfate is designated chemically as 0-2, 6-Diamino-2, 6-dideoxy-β -L-idopyranosyl-(1→3)-0-β -D-ribofuranosyl-(1→5)-0-[2-amino-2-deoxy-α -D-glucopyranosyl-(1→4)]-2-deoxystreptamine sulfate (salt). The molecular formula is C23H45N5O14•xH2SO4, with a molecular weight of 615.64 (base).
Its structural formula is:
Each capsule, for oral administration, contains paromomycin sulfate equivalent to 250 mg paromomycin. Each capsule also contains the following inactive ingredients: FD&C Blue # 1, D&C Red # 28, FD&C Red # 40, gelatin and titanium dioxide. The imprinting ink for the 250 mg capsule contains D&C yellow #10, FD&C blue # 1, FD&C blue # 2, FD&C red # 40, iron oxide black, pharmaceutical shellac glaze, and propylene glycol.Close
- CLINICAL PHARMACOLOGY
The in-vitro and in-vivo antibacterial action of paromomycin closely parallels that of neomycin. It is poorly absorbed after oral administration, with almost 100% of the drug recoverable in the stool.Close
- INDICATIONS AND USAGE
Paromomycin sulfate is indicated for intestinal amebiasis–acute and chronic (NOTE-It is not effective in extraintestinal amebiasis); management of hepatic coma–as adjunctive therapy.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Paromomycin Sulfate Capsules and other antibacterial drugs, Paromomycin Sulfate Capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.Close
Paromomycin sulfate is contraindicated in individuals with a history of previous hypersensitivity reactions to it. It is also contraindicated in intestinal obstruction.Close
Prescribing Paromomycin Sulfate Capsules in the absence of a proven or strongly suspected bacterial infection or a prophylacticindication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
The use of this antibiotic, as with other antibiotics, may result in an overgrowth of nonsusceptible organisms, including fungi. Constant observation of the patientis essential. If new infections caused by nonsusceptible organisms appear during therapy, appropriate measures should be taken. The drug should be used with caution in individuals with ulcerative lesions of the bowel to avoid renal toxicity through inadvertent absorption.
Information for Patients
Patients should be counseled that antibacterial drugs including Paromomycin Sulfate Capsules should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When Paromomycin Sulfate Capsules is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Paromomycin Sulfate Capsules or other antibacterial drugs in the future.
See DOSAGE AND ADMINISTRATION section.
- ADVERSE REACTIONS
Nausea, abdominal cramps, and diarrhea have been reported inpatients on doses over 3 g daily.Close
- DOSAGE AND ADMINISTRATION
Intestinal amebiasis: Adults and Pediatric Patients: Usual dose—25 to 35 mg/kg body weight daily, administered in three doses with meals, for five to ten days.
Management of hepatic coma:
Adults: Usual dose—4 g daily in divided doses, given at regular intervals for five to six days.Close
- HOW SUPPLIED
Paromomycin Sulfate Capsules, USP each contain paromomycin sulfate equivalent to 250 mg paromomycin, are supplied as follows:
NDC 23155-038-01: Bottles of 100
The capsule is Dark Blue Opaque /White Opaque, imprinted with “HP 38” in black ink on the cap and on the body.
Store at 20°-25°C (68°-77°F) [See USP controlled Room Temperature]
Protect from moisture.
Preserve in tight containers as defined in the USP.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088
Heritage Pharmaceuticals Inc.
Eatontown, NJ 07724
MF # 0241-02Close
- PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
Paromomycin Sulfate Capsules, USP, 250 mg -100 count
- INGREDIENTS AND APPEARANCE
paromomycin sulfate capsule
Product Information Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:23155-038 Route of Administration ORAL DEA Schedule Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength PAROMOMYCIN SULFATE (PAROMOMYCIN) PAROMOMYCIN 250 mg Inactive Ingredients Ingredient Name Strength FD&C BLUE NO. 1 D&C RED NO. 28 FD&C RED NO. 40 GELATIN TITANIUM DIOXIDE D&C YELLOW NO. 10 FD&C BLUE NO. 2 FERROSOFERRIC OXIDE SHELLAC PROPYLENE GLYCOL Product Characteristics Color WHITE (White opaque) , BLUE (Dark blue opaque) Score no score Shape CAPSULE Size 19mm Flavor Imprint Code HP;38 Contains Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:23155-038-01 100 in 1 BOTTLE Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA065173 10/22/2009 Labeler - Heritage Pharmaceuticals Inc. (780779901) Establishment Name Address ID/FEI Business Operations Emcure Pharmaceuticals USA 189630168 MANUFACTURE(23155-038)